Netherlands· NL-41bbb5f4a64a
Candesartan cilexetil Xiromed 16 mg tabletten
A candesartan product containing candesartancilexetil, registered in Netherlands by Medical Valley Invest AB. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Candesartan is registered in 16 of 19 countries.
Countries holding a registration under ATC C09CA06 (candesartan), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Candesartan · ATC C09CA06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of candesartan costs, country by country.
Normalised to the WHO defined daily dose (8 mg), the median price runs from $0.15 in Italy to $0.36 in Switzerland — a ×2.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Candesartan · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.36
- ES Spain$0.21
- IT Italy$0.15
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CANDESARTANCILEXETIL
- Manufacturer
- Medical Valley Invest AB
- Country
- Netherlands (NL)
- ATC code
- C09CA06
- ATC class
- Candesartan
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id109134
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for candesartan.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Candesartan · interactions on record
81 records
81 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Candesartan in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1393e70-dc91-4c74-b60f-43facb0159f8 GET /v1/drugs/f1393e70-dc91-4c74-b60f-43facb0159f8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h109134_smpc.pdf",
"strength": null,
"atc_label": "Candesartan",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg109134",
"excipients": [
"DIETHYLEENGLYCOLMONOETHYLETHER",
"HYPROLOSE (E 463)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"MAÏSZETMEEL"
],
"substances": [
"CANDESARTANCILEXETIL"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h109134.pdf",
"authorised_at": "2012/06/19",
"procedure_number": "NL/H/2270/003",
"dispensing_status": "Uitsluitend recept",
"registration_number": "109134",
"additional_monitoring": "N"
}See everything about candesartan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.